326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Equities Feed Kaden Berrington-January 18, 2021 0. PRLD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Norges Bank, and Rhumbline Advisers. 3 Quality Buy and Hold Stocks for Long Term Investors. PRLD: NASDAQ: Common Stock Price Change Change Percent Stock Price Last Traded ; 3.40: 4.27%: 83.00: 13:09:15: Open Price Low Price High Price Close Price Prev Close; 80.00: 79.30: 85.00: 79.60: more quote information » Recent News. Want to see which stocks are moving? Free forex prices, toplists, indices and lots more. Miguel Garrison-December 25, 2020 0. Prelude Therapeutics PRLD . The Prelude Therapeutics Incorporated stock price fell by -4.80% on the last day (Wednesday, 3rd Mar 2021) from $62.53 to $59.53. Prelude Therapeutics Inc. Watch list CreatePRLDAlert. DOW 31,148.24. Business. Stock analysis for Prelude Therapeutics Inc (PRLD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. PRLD stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Squarepoint Ops LLC, and Price T Rowe Associates Inc. MD. All quotes are in local exchange time. © 2021, Nasdaq, Inc. All Rights Reserved. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO. Stocks to Trade Nora Atcheson-January 21, 2021 0. 533,214 shares changed hands during mid-day trading, an increase of 58% from the average session volume of 337,645 shares. In depth view into PRLD (Prelude Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. High institutional ownership can be a signal of strong market trust in this company. Morgan Stanley does not see either upside or downside right now giving PRLD "Equal Weight" on their last update on December 16, 2020. Learn more. Prelude Therapeutics Incorporated Common Stock (PRLD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. S&P 500 3,841.94 When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Compare Top Brokerages Here. Touch device users, explore by touch or with swipe gestures. These symbols will be available throughout the site during your session. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … The consensus price target as assigned by Wall Street analysts is $48, which translates to bears needing to reduce their stock price by -35.53% from its current value. Get daily stock … Type a symbol or company name. Find the latest Institutional Holdings data for Prelude Therapeutics Incorporated Common Stock (PRLD) at Nasdaq.com. Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD.". Analyst projections state that PRLD is forecast to be at a low of $37 and a high of $60. This suggests that the stock has a possible downside of 9.0%. QQQ 331.36. Prelude Therapeutics Inc () Stock Market info Recommendations: Buy or sell Prelude Therapeutics stock? Payout History. Prelude Therapeutics (NASDAQ:PRLD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. Sign Up. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Company Profile. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. One share of PRLD stock can currently be purchased for approximately $56.06. Wall Street analysts have given Prelude Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Prelude Therapeutics Inc. Get the latest Prelude Therapeutics Incorporated PRLD detailed stock quotes, stock … MarketBeat's community ratings are surveys of what our community members think about Prelude Therapeutics and other stocks. © American Consumer News, LLC dba MarketBeat® 2010-2021. View which stocks are hot on social media with MarketBeat's trending stocks report. Payout Estimate. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRLD, but not buy additional shares or sell existing shares. Prelude Therapeutics' management team includes the following people: Start Your Risk-Free Trial Subscription Here, Russia to make Sputnik V vaccine in Italy; a 1st in EU, Technology rebound leads stocks higher on Wall Street, Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play, GE, AerCap join air leasing businesses in $30 billion deal, ChargePoint Stock is a Speculative EV Play Only for the Nimble and Risk-Tolerant, US officials: report on oil and gas sale ban due by summer, FlexShopper Stock: Small Price, Big Upside, Casey's General Stores is Still a Good Buy, Why Visa (NYSE:V) Stock Deserves More Credit, Thor Industries (NYSE:THO) Deserves A Spot In Your Pantheon Of Stocks, Texas Roadhouse Looks Like a Post-Pandemic Winner, Purple Innovation Attempts Rebound After Earnings Dive, Great Time to Buy Goodyear Tires (NYSE: GT) Stock Here, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Prelude Therapeutics Becomes Oversold (PRLD), Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares, Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, Prelude, Onconova plan multimillion-dollar stock sales, Prelude Therapeutics Announces Pricing of Upsized Public Offering, Prelude Therapeutics Announces Launch of Proposed Public Offering, Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation, Prelude Therapeutics Announces Third Quarter 2020 Financial Results, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. After the end of Prelude Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company. PRLD | Complete Prelude Therapeutics Inc. stock news by MarketWatch. Please opt-in to receive news and information about Nasdaq’s services. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Prelude Therapeutics S-1 Shows Registration For 1.75M Common Stock Offering Benzinga Newsdesk Mon, 04 Jan 2021 16:11:51 -0500 Stocks That Hit 52-Week Highs On Thursday Benzinga … What predictions are top-rated research analysts making about Prelude Therapeutics (NASDAQ:PRLD)? The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. China gives approval for broader use of Sinovac vaccine. Type a symbol or company name. (Add your “underperform” vote.). PRLD: NASDAQ (Stock) Prelude Therapeutics Inc Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% PRLD: NASDAQ (Stock) Prelude Therapeutics Inc Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% Watchlist Overview. Corning (GLW) Stable On Friday, Recently Received An Order For Glass For Diagnostic Robots . Identify stocks that meet your criteria using seven unique stock screeners. Prelude Therapeutics (PRLD) share price, charts, trades & the UK's most popular discussion forums. Trading Ideas . ), Prelude Therapeutics has received 6 “underperform” votes. On average, they expect Prelude Therapeutics' share price to reach $51.00 in the next year. Get the latest Prelude Therapeutics Incorporated PRLD detailed stock quotes, stock data, Real-Time ECN, … 4 brokers have issued 1 year price objectives for Prelude Therapeutics' stock. Stock prices may also move more quickly in this environment. So if that suits your style you could check each stock one by one or … According … Zero analysts have provided estimates for Prelude Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.58) and the highest estimate coming in at ($0.47). Analysts Predicting a Spike in Prelude Therapeutics Incorporated (NASDAQ:PRLD)? NASDAQ › Prelude Therapeutics Incorporated (NASDAQ:PRLD) Interval. Analysts Predicting a Spike in Prelude Therapeutics Incorporated (NASDAQ:PRLD)? … © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. your username. Here’s Why SunPower (SPWR) and Enphase (ENPH) Are Among The Best Green Stocks. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. See what's happening in the market right now with MarketBeat's real-time news feed. Welcome! The initial public offering price is $19.00 per share. Investors who anticipate trading during these times are strongly advised to use limit orders. View Prelude Therapeutics Incorporated PRLD investment & stock information. Prelude Therapeutics (NASDAQ:PRLD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) traded down 6.7% on Tuesday . Analyst Rating View All … Most Recent Rating. View PRLD's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. your password Learn about financial terms, types of investments, trading strategies and more. MarketBeat: Week in Review 2/1 – 2/5. Fundamental company data provided by Zacks Investment Research. View analysts' price targets for Prelude Therapeutics or view top-rated stocks among Wall Street analysts. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Equities analysts forecast that Prelude Therapeutics Incorporated (NASDAQ:PRLD) will announce earnings of ($0.53) per share for the current quarter, Zacks Investment Research reports. Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation Just because a business does not make any money, does not mean that the stock will go down. Date Rating Action Authority Current Price Target Price; 2020 … Prelude Therapeutics Incorporated (NASDAQ:PRLD): Trading Information. Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. This is our initial public offering and no public market currently exists for our common stock. Earnings for Prelude Therapeutics are expected to grow in the coming year, from ($3.02) to ($2.10) per share. A high-level overview of Prelude Therapeutics Incorporated (PRLD) stock. (NASDAQ : PRLD) ( ) PRLD PreMarket: $ () as of AM. PRLD U.S.: Nasdaq. Hot News. Check if PRLD has a Buy or Sell Evaluation. News & Research. Minute Hour Daily Get our free advanced charting studies, portfolio tools, and more. and has now fallen 3 days in a row. Prelude Therapeutics Incorporated (NASDAQ:PRLD) dropped 6.7% during mid-day trading on Tuesday . Prelude Therapeutics Incorporated PRLD:NASDAQ . Create your Watchlist to save your favorite quotes on Nasdaq.com. Copy and paste multiple symbols separated by spaces. The company reported ($5.25) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $4.82. 1d 5d 1m 3m 1y 5y YTD. Get Prelude Therapeutics, Inc.'s stock price today. ET). Get the latest Prelude Therapeutics (PRLD) stock price quote with real-time news, financials, charts and other important investing information. Sign-up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. There are always plenty of stocks that insiders are buying. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The stock traded as low as $69.00 and last traded at $69.93. Analysts at Barclays initiated coverage on shares of Prelude Therapeutics (NASDAQ:PRLD) in a research report issued on Tuesday, Briefing.com reports. In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock. PRLD stock quote, chart and news. Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its quarterly earnings data on Tuesday, November, 10th. PRLD Stock Price (NASDAQ), Score, Forecast, Predictions, and Prelude Therapeutics Incorporated News. View analyst ratings for Prelude Therapeutics or view top-rated stocks. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View live PRELUDE THERAPEUTICS INC chart to track its stock's price action. According to Zacks, “Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. PRLD’s current price is a discount, trading about -8.59% off its 52-week high of $82.64. Please log in to your account or sign up in order to add this asset to your watchlist. Get Prelude Therapeutics Inc (PRLD:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Get today's Prelude Therapeutics Inc stock price and latest PRLD news as well as Prelude real-time stock quotes, technical analysis, full financials and more. You may vote once every thirty days. Get short term trading ideas from the MarketBeat Idea Engine. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. When autocomplete results are available use up and down arrows to review and enter to select. NasdaqGS:PRLD Insider Trading Volume December 25th 2020. (Hint: insiders have been buying them). The company issued 8,300,000 shares at $17.00-$19.00 per share. New. Check out the latest ideas and forecasts on PRELUDE THERAPEUTICS INC from our top authors — they share predictions and technical outlook of the market. The total size of the offering was $158,175,000 based on an initial share price of $19.00. NASDAQ:NKTR: NASDAQ:AGIO: NASDAQ:PRLD: NASDAQ:ALKS: NASDAQ:OPK: Price Information: Current Price: $22.31: $48.89: $56.79: $19.28: $4.22: 52 Week Range: ... Stock Ideas and Recommendations. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware. The reported ($5.25) earnings per share (EPS) for the … The chart below shows the one year performance of PRLD shares: Looking at the chart above, PRLD's low point in its 52 week range is $23.6931 per share, with $95.375 as the 52 week high … During the day the stock … Business. Prelude Therapeutics PRLD WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange. The firm set an “overweight” rating and a $80.00 price target on the stock. The price target was set to $38.00 → $47.00. Prelude Therapeutics' stock is owned by many different retail and institutional investors. NasdaqGS:PRLD Insider Trading Volume December 25th 2020. To see all exchange delays and terms of use please see disclaimer. Analyzing Prelude Therapeutics (NASDAQ:PRLD) stock? MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. PRLD US. All rights reserved. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. PRLD: Get the latest Prelude Therapeutics stock price and detailed information including PRLD news, historical charts and realtime prices. Barclays‘s price target suggests a potential upside of 51.29% from the stock’s previous close. We're sharing our advanced charting and portfolio tools with you! View detailed financial information, real-time news, videos, quotes and analysis on Prelude Therapeutics, Inc. (NASDAQ:PRLD). Create your account for free access. Their forecasts range from $37.00 to $80.00. Tag: NASDAQ:PRLD. Prelude Therapeutics employs 55 workers across the globe. According to analysts' consensus price target of $51.00, Prelude Therapeutics has a forecasted downside of 9.0% from its current price of $56.06. Prelude Therapeutics Incorporated Common Stock, Do Not Sell My Personal Information (CA Residents Only). Solar companies and other main players in the solar industry have witnessed significant price … A high-level overview of Prelude Therapeutics Incorporated (PRLD) stock. All quotes are in local exchange time. Learn everything you need to know about successful options trading with this three-part video course. View the latest PRLD financial statements, income statements and financial ratios. Prelude Therapeutics has received 4 “outperform” votes. See the complete list of world stock indexes with points and percentage change, volume, intraday highs and lows, 52 week range, and day charts. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Their average twelve … MarketBeat just released five new trading ideas, but Prelude Therapeutics wasn't one of them. Add to Portfolio; Download Data; Analyze PRLD; Today's Top 50 Trending Stocks. Prelude Therapeutics' lock-up period expires on Wednesday, March 24th. Stock (NASDAQ) PRLD Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% PRLD: NASDAQ (Stock) Prelude Therapeutics Inc Dividend policy None Price as of: FEB 19, 06:12 AM EDT $74.47 -1.8 -2.36% PRLD: NASDAQ (Stock… Get daily stock ideas top-performing Wall Street analysts. View Prelude Therapeutics' earnings history. Email. Add to Watchlist. Prelude Therapeutics has received a consensus rating of Hold. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. TradingView UK. Add to ... Trade PRLD stock for free with recommended broker TD Ameritrade. 76.21% of the stock of Prelude Therapeutics is held by institutions. A number of other equities analysts also […] The consensus among Wall Street research analysts is that investors should "hold" Prelude Therapeutics stock. Find market predictions, PRLD financials and market news. With the company’s most recent per share price at $76.1 changing hands around -$0.36 or 0% at last look, the market valuation stands at $4.17 Billion. In the latest trading session, 1,732,814 Prelude Therapeutics Incorporated(NASDAQ:PRLD) shares changed hands as the company’s beta touched 0. Historical Ratings. Prelude Therapeutics Incorporated Stock Forecast NASDAQ:PRLD Price Target and Analyst Ratings. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Tag: PRLD stock. Prelude Therapeutics had issued 8,325,000 shares in its IPO on September 25th. Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. Compare. ET) and the After Hours Market (4:00-8:00 p.m. There are always plenty of stocks that insiders are buying. Complete stock market coverage with breaking news, analysis, stock quotes, before & after hours market data, research and earnings Receive a free world-class investing education from MarketBeat. Miguel Garrison-December 25, 2020 0. Here's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation Just because a business does not make any money, does not mean that the stock will go down. Annual stock financials by MarketWatch. Earnings Prelude Therapeutics (NASDAQ:PRLD) Earnings Information. Prelude Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021. Vote “Outperform” if you believe PRLD will outperform the S&P 500 over the long term. The company can be reached via phone at 302-644-5427 or via email at [email protected]. The stock traded as low as $69.00 and last traded at … Close price at the end of the last trading day (Friday, 5th Mar 2021) of the PRLD stock was $56.79. Export data to Excel for your own analysis. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Looking for new stock ideas? (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. Prelude Therapeutics Incorporated Common Stock (PRLD) Nasdaq Listed; Nasdaq 100; ... PRLD Most Active Options. A number of brokerages have […] Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View real-time stock prices and stock quotes for a full financial overview. Prelude Therapeutics does not currently pay a dividend. The stock had previously closed at $74.99. We have been approved to list our common stock on The Nasdaq Global S PRLD (Add your “outperform” vote. Some companies that are related to Prelude Therapeutics include BridgeBio Pharma (BBIO), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), GW Pharmaceuticals (GWPH), Allakos (ALLK), TG Therapeutics (TGTX), Maravai LifeSciences (MRVI), Evotec (EVTCY), Blueprint Medicines (BPMC) and Turning Point Therapeutics (TPTX). The official website for Prelude Therapeutics is www.preludetx.com. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View the latest Prelude Therapeutics Inc. (PRLD) stock price, news, historical charts, analyst ratings and financial information from WSJ. NASDAQ:PRLD - Prelude Therapeutics Stock Price Target and Predictions. Unlock These Features . Prelude Therapeutics last issued its earnings data on November 10th, 2020. View Prelude Therapeutics Incorporated PRLD investment & stock information. This is 1.77% more than the trading day before Thursday, 4th Mar 2021. View our full suite of financial calendars and market data tables, all for free. View all of PRLD's competitors. WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial... Seeking Alpha - 5 months ago Prelude Therapeutics Finalizes IPO Terms Prelude … Prelude Therapeutics (PRLD) charts [DMA,SMA,EMA] Technical analysis [MACD,ADX,RSI,CCI] indicators. View live PRELUDE THERAPEUTICS INC chart to track its stock's price action. WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been … Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days. Top institutional shareholders include BlackRock Inc. (1.46%), UBS Asset Management Americas Inc. (1.18%), Price T Rowe Associates Inc. MD (0.89%), Northern Trust Corp (0.26%), Charles Schwab Investment Management Inc. (0.16%) and Nuveen Asset Management LLC (0.08%). Prelude Therapeutics has a market capitalization of $2.45 billion. Do Not Sell My Information. Hot News. After Hours. During the day the stock fluctuated … It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. There are currently 3 hold ratings and 1 buy rating for the stock. Vote “Underperform” if you believe PRLD will underperform the S&P 500 over the long term. You can opt out at any time. Prelude Therapeutics PRLD Current Price 09 Feb, 2021 A $15 million deal with the U.S. Defense Department was recently signed by technology … S&P 500 3,886.83. Shares of PRLD can be purchased through any online brokerage account. Quote; Premarket; Insiders; Financials; Earnings; Filings; Analysts; Profile; Historical; Performance; Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield. Prelude Therapeutics has received 60.00% “underperform” votes from our community. Learn more. Find market predictions, PRLD financials and market news. Prelude Therapeutics (NASDAQ:PRLD) Price Target and Consensus Rating 3 Wall Street analysts have issued ratings and price targets for Prelude Therapeutics in the last 12 months. View our earnings forecast for Prelude Therapeutics. Last 30 Days. View PRLD's most recent analyst ratings, analyst estimates and price targets at MarketBeat. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Investors may trade in the Pre-Market (4:00-9:30 a.m. Log into your account. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Prelude Therapeutics does not have a long track record of dividend growth.
Is Carbon Fiber Bulletproof, Alma Har'el Height, Animated Films On Bbc Iplayer, Ark Pc Pve Trading Discord, Raiders Of The Lost Ark Comic Book Value, Revenge Of The Green Dragons Article, William Seabrook Dc, Scientific Officer Qualification,